340 related articles for article (PubMed ID: 33190043)
1. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.
Beg S; Bareja R; Ohara K; Eng KW; Wilkes DC; Pisapia DJ; Zoughbi WA; Kudman S; Zhang W; Rao R; Manohar J; Kane T; Sigouros M; Xiang JZ; Khani F; Robinson BD; Faltas BM; Sternberg CN; Sboner A; Beltran H; Elemento O; Mosquera JM
Transl Oncol; 2021 Jan; 14(1):100944. PubMed ID: 33190043
[TBL] [Abstract][Full Text] [Related]
2. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
Oberg JA; Glade Bender JL; Sulis ML; Pendrick D; Sireci AN; Hsiao SJ; Turk AT; Dela Cruz FS; Hibshoosh H; Remotti H; Zylber RJ; Pang J; Diolaiti D; Koval C; Andrews SJ; Garvin JH; Yamashiro DJ; Chung WK; Emerson SG; Nagy PL; Mansukhani MM; Kung AL
Genome Med; 2016 Dec; 8(1):133. PubMed ID: 28007021
[TBL] [Abstract][Full Text] [Related]
3. Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer.
O'Brien TD; Jia P; Xia J; Saxena U; Jin H; Vuong H; Kim P; Wang Q; Aryee MJ; Mino-Kenudson M; Engelman JA; Le LP; Iafrate AJ; Heist RS; Pao W; Zhao Z
Methods; 2015 Jul; 83():118-27. PubMed ID: 25913717
[TBL] [Abstract][Full Text] [Related]
4. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
[TBL] [Abstract][Full Text] [Related]
5. Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice.
Imperial R; Nazer M; Ahmed Z; Kam AE; Pluard TJ; Bahaj W; Levy M; Kuzel TM; Hayden DM; Pappas SG; Subramanian J; Masood A
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31546879
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
Cohen D; Hondelink LM; Solleveld-Westerink N; Uljee SM; Ruano D; Cleton-Jansen AM; von der Thüsen JH; Ramai SRS; Postmus PE; Graadt van Roggen JF; Hoppe BPC; Clahsen PC; Maas KW; Ahsmann EJM; Ten Heuvel A; Smedts F; van Rossem RN; van Wezel T
J Thorac Oncol; 2020 Jun; 15(6):1000-1014. PubMed ID: 32014610
[TBL] [Abstract][Full Text] [Related]
8. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
9. Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel.
Dufresne A; Attignon V; Ferrari A; Tonon L; Boyault S; Tabone-Eglinger S; Cassier P; Trédan O; Corradini N; Vinceneux A; Swalduz A; Viari A; Chabaud S; Pérol D; Blay JY; Saintigny P
Cancer Med; 2024 Apr; 13(7):e7115. PubMed ID: 38553950
[TBL] [Abstract][Full Text] [Related]
10. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
[TBL] [Abstract][Full Text] [Related]
11. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
12. Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.
LaDuca H; Farwell KD; Vuong H; Lu HM; Mu W; Shahmirzadi L; Tang S; Chen J; Bhide S; Chao EC
PLoS One; 2017; 12(2):e0170843. PubMed ID: 28152038
[TBL] [Abstract][Full Text] [Related]
13. The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Drenner K; Basu GD; Goodman LJ; Ozols AA; LoBello JR; Royce T; Gordon MS; Borazanci EH; Steinbach MA; Trent J; Sharma S
Oncotarget; 2021 Aug; 12(18):1836-1847. PubMed ID: 34504655
[TBL] [Abstract][Full Text] [Related]
14. Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience.
Marks LJ; Oberg JA; Pendrick D; Sireci AN; Glasser C; Coval C; Zylber RJ; Chung WK; Pang J; Turk AT; Hsiao SJ; Mansukhani MM; Glade Bender JL; Kung AL; Sulis ML
Front Pediatr; 2017; 5():265. PubMed ID: 29312904
[TBL] [Abstract][Full Text] [Related]
15. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors.
Martínez-Fernández P; Pose P; Dolz-Gaitón R; García A; Trigo-Sánchez I; Rodríguez-Zarco E; Garcia-Ruiz M; Barba I; Izquierdo-García M; Valero-Garcia J; Ruiz C; Lázaro M; Carbonell P; Gargallo P; Méndez C; Ríos-Martín JJ; Palmeiro-Uriach A; Camarasa-Lillo N; Forteza-Vila J; Calabria I
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33947144
[TBL] [Abstract][Full Text] [Related]
17. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
[TBL] [Abstract][Full Text] [Related]
18. Utility of ultrasound-guided liver tumor biopsy for next-generation sequencing-based clinical sequencing.
Eso Y; Kou T; Nagai H; Kim YH; Kanai M; Matsumoto S; Mishima M; Arasawa S; Iguchi E; Nakamura F; Takeda H; Takai A; Takahashi K; Ueda Y; Muto M; Seno H
Hepatol Res; 2019 May; 49(5):579-589. PubMed ID: 30645782
[TBL] [Abstract][Full Text] [Related]
19. Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing.
Lam SW; Cleton-Jansen AM; Cleven AHG; Ruano D; van Wezel T; Szuhai K; Bovée JVMG
J Mol Diagn; 2018 Sep; 20(5):653-663. PubMed ID: 30139549
[TBL] [Abstract][Full Text] [Related]
20. SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA.
Balan J; Jenkinson G; Nair A; Saha N; Koganti T; Voss J; Zysk C; Barr Fritcher EG; Ross CA; Giannini C; Raghunathan A; Kipp BR; Jenkins R; Ida C; Halling KC; Blackburn PR; Dasari S; Oliver GR; Klee EW
Front Genet; 2021; 12():739054. PubMed ID: 34745213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
